
Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.
Top HCV articles of the year on Specialty Pharmacy Times.
[<a href="//storify.com/pharmacytimes/top-hepatitis-c-news-of-2016" target="_blank">View the story "Top Hepatitis C News of 2016" on Storify</a>]






